Table 1. Progression of IPS after... | American Society of Hematology

Table 1.

Progression of IPS after allo-SCT

	Lung pathology score, mean ± SEM			Total BALF cellularity, × 10⁶, mean ± SEM
Week	Syngeneic	Allogeneic	Syngeneic	Allogeneic	Syngeneic	Allogeneic
1	0 ± 0	0 ± 0	0.3 ± 0.1	0.5 ± 0.1	0.003 ± 0.001	0.2 ± 0.1^*
2	0.1 ± 0.1	0.8 ± 0.1^*	0.3 ± 0.1	1.5 ± 0.3^*	0.009 ± 0.001	0.7 ± 0.1^*
4	0.1 ± 0.1	3.8 ± 0.3^*	0.4 ± 0.1	2.5 ± 0.3^*	0.026 ± 0.008	1.0 ± 0.2^*
6	0.3 ± 0.1	6.7 ± 0.4^*	0.8 ± 0.1	2.5 ± 0.4^*	0.140 ± 0.040	1.2 ± 0.3^*

	Lung pathology score, mean ± SEM			Total BALF cellularity, × 10⁶, mean ± SEM
Week	Syngeneic	Allogeneic	Syngeneic	Allogeneic	Syngeneic	Allogeneic
1	0 ± 0	0 ± 0	0.3 ± 0.1	0.5 ± 0.1	0.003 ± 0.001	0.2 ± 0.1^*
2	0.1 ± 0.1	0.8 ± 0.1^*	0.3 ± 0.1	1.5 ± 0.3^*	0.009 ± 0.001	0.7 ± 0.1^*
4	0.1 ± 0.1	3.8 ± 0.3^*	0.4 ± 0.1	2.5 ± 0.3^*	0.026 ± 0.008	1.0 ± 0.2^*
6	0.3 ± 0.1	6.7 ± 0.4^*	0.8 ± 0.1	2.5 ± 0.4^*	0.140 ± 0.040	1.2 ± 0.3^*

B6D2F1 mice received syngeneic or allogeneic SCT as in Figure 1. Recipients of allogeneic SCT develop significant lung pathology and alterations in total BALF cellularity and T-cell counts compared to syngeneic controls. Data presented are from 2 experiments representative of 3 and are presented as mean ± SEM; n = 8 to 10 per group per time point.

P < .01

View Large

This Feature Is Available To Subscribers Only